Objective
to report the 5-year clinical outcomes of treatment of patients with ACS with Titanium-nitride-oxide (TiNO) coated stents compared to Everolimus-eluting stents (EES)
Study
multicentre 2:1 ratio, randomised trial
Population
patients with ACS
Endpoints
main composite of cardiac death, MI or target-lesion revascularisation at 5 years
Conclusion
in patients with acute coronary syndromes the major adverse event rate at 5 years was not different between treatment with TiNO coated stents or Everolimus-eluting stents
Boisset et al. JAMA Cardiol 2023; 8:703-708
